Short Interest in Evogene Ltd. (NASDAQ:EVGN) Rises By 107.5%

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 33,200 shares, an increase of 107.5% from the February 13th total of 16,000 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 41,400 shares, the days-to-cover ratio is presently 0.8 days.

Evogene Stock Performance

Shares of EVGN stock opened at $1.43 on Friday. Evogene has a one year low of $1.20 and a one year high of $9.00. The company has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.97. The firm has a market capitalization of $7.67 million, a price-to-earnings ratio of -0.32 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The company had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. During the same period in the previous year, the firm earned ($1.30) earnings per share.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on EVGN shares. Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a report on Friday, March 7th. StockNews.com started coverage on shares of Evogene in a research report on Monday, March 10th. They set a “sell” rating for the company.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene as of its most recent SEC filing. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.